GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bionik Laboratories Corp (OTCPK:BNKL) » Definitions » Piotroski F-Score

Bionik Laboratories (Bionik Laboratories) Piotroski F-Score : 0 (As of Apr. 27, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Bionik Laboratories Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bionik Laboratories has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Bionik Laboratories's Piotroski F-Score or its related term are showing as below:


Bionik Laboratories Piotroski F-Score Historical Data

The historical data trend for Bionik Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionik Laboratories Piotroski F-Score Chart

Bionik Laboratories Annual Data
Trend Dec14 Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 4.00 3.00 4.00 3.00

Bionik Laboratories Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 2.00 4.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Net Income was -1.384 + -1.129 + -1.076 + -1.356 = $-4.95 Mil.
Cash Flow from Operations was -1.162 + -0.955 + -0.513 + -0.757 = $-3.39 Mil.
Revenue was 0.243 + 0.486 + 0.575 + 0.501 = $1.81 Mil.
Gross Profit was 0.168 + 0.298 + 0.271 + 0.254 = $0.99 Mil.
Average Total Assets from the begining of this year (Mar22)
to the end of this year (Mar23) was
(4.676 + 4.003 + 3.83 + 3.685 + 3.362) / 5 = $3.9112 Mil.
Total Assets at the begining of this year (Mar22) was $4.68 Mil.
Long-Term Debt & Capital Lease Obligation was $2.39 Mil.
Total Current Assets was $2.78 Mil.
Total Current Liabilities was $2.31 Mil.
Net Income was -0.451 + -1.268 + -6.984 + -1.705 = $-10.41 Mil.

Revenue was 0.671 + 0.228 + 0.183 + 0.191 = $1.27 Mil.
Gross Profit was 0.541 + 0.147 + 0.133 + 0.133 = $0.95 Mil.
Average Total Assets from the begining of last year (Mar21)
to the end of last year (Mar22) was
(8.786 + 8.677 + 12.462 + 5.98 + 4.676) / 5 = $8.1162 Mil.
Total Assets at the begining of last year (Mar21) was $8.79 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $4.59 Mil.
Total Current Liabilities was $1.49 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bionik Laboratories's current Net Income (TTM) was -4.95. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bionik Laboratories's current Cash Flow from Operations (TTM) was -3.39. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar22)
=-4.945/4.676
=-1.0575278

ROA (Last Year)=Net Income/Total Assets (Mar21)
=-10.408/8.786
=-1.18461188

Bionik Laboratories's return on assets of this year was -1.0575278. Bionik Laboratories's return on assets of last year was -1.18461188. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Bionik Laboratories's current Net Income (TTM) was -4.95. Bionik Laboratories's current Cash Flow from Operations (TTM) was -3.39. ==> -3.39 > -4.95 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=2.39/3.9112
=0.61106566

Gearing (Last Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=0/8.1162
=0

Bionik Laboratories's gearing of this year was 0.61106566. Bionik Laboratories's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar23)=Total Current Assets/Total Current Liabilities
=2.778/2.309
=1.20311823

Current Ratio (Last Year: Mar22)=Total Current Assets/Total Current Liabilities
=4.585/1.492
=3.0730563

Bionik Laboratories's current ratio of this year was 1.20311823. Bionik Laboratories's current ratio of last year was 3.0730563. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Bionik Laboratories's number of shares in issue this year was 6.976. Bionik Laboratories's number of shares in issue last year was 5.914. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.991/1.805
=0.54903047

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.954/1.273
=0.74941084

Bionik Laboratories's gross margin of this year was 0.54903047. Bionik Laboratories's gross margin of last year was 0.74941084. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar22)
=1.805/4.676
=0.38601369

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar21)
=1.273/8.786
=0.1448896

Bionik Laboratories's asset turnover of this year was 0.38601369. Bionik Laboratories's asset turnover of last year was 0.1448896. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+0+0+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bionik Laboratories has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Bionik Laboratories  (OTCPK:BNKL) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Bionik Laboratories Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Bionik Laboratories's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionik Laboratories (Bionik Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
80 Coolidge Hill Road, Watertown, MA, USA, 02472
Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and innovative robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.
Executives
Remi Gaston-dreyfus director, 10 percent owner 46 RUE PIERRE CHARRON, PARIS I0 75008
Charles Matine director 7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017
Andre-jacques Auberton-herve director, officer: Chairman 18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700
Daniel Gonsalves officer: Executive Vice President & CFO 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Loren W. Wass officer: See Remarks 34 HOG HILL ROAD, PEPPERELL MA 01463
Joseph R Martin director
Audrey Thevenon director 4500 WESTBROOK LANE, KENSINGTON MD 20895
Peter Gerald Malone director
Russo Richard Paul Jr officer: Chief Financial Officer 20 PLUNKETT WAY, TEWKSBURY MA 01876
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
Timothy A. Mccarthy officer: Chief Commercialization Office C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9
Eric Michel Dusseux director 1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300
Jules Marc Fried officer: VP - U.S. Operations C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Hermano Igo Krebs officer: Chief Science Officer C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Marc Mathieu director 716 BROOKS AVENUE, VENICE CA 90291